Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM9O8DT)

• Drug Name: L-Tyrosine Drug Info
• Synonyms: DTY; Rxosine; Tirosina; Tyr; Tyrosine; Tyrosinum; Tirosina [Spanish]; Tyrosine Power; Tyrosinum [Latin]; Melanin synthesized from Tyr substrate catalyzed by tyrosinase for 6 hrs; L-Tyrosin; L-Tyrosine hydrochloride; Melanin synthesized from Tyr substrate catalyzed by tyrosinase for 6 hrs, oxidized with hydrogen peroxide; P-Tyrosine; TYR NH3+ COOH; Tyrosine (VAN); Tyrosine [USAN:INN]; Free-Form L-Tyrosine; H-Tyr-OH; L-Tyrosine (9CI); L-Tyrosine (JAN); L-Tyrosine, homopolymer; L-Tyrosine, monomer; L-p-Tyrosine; Melanin synthesized from Tyr substrate catalyzed by tyrosinase, brominated with N-bromosuccinimide; Tyrosine (USP/INN); Beta-(p-Hydroxyphenyl)alanine; Melanin synthesized from Tyr substrate catalyzed by tyrosinase for 6 hrs, oxidized with hydrogen peroxide, <3 kd fraction; Tyrosine, L-(8CI); DD69927C-C6A8-4BC6-8E9A-0AB423B176E7; L-(-)-Tyrosine; Melanin synthesized from Tyr substrate catalyzed by tyrosinase, sulfonated using sulfur trioxide/DMF complex for 1.5-7 hours; Alpha-Amino-beta-(4-hydroxyphenyl)propionic acid; L-2-Amino-3-p-hydroxyphenylpropanoic acid; (-)-alpha-Amino-p-hydroxyhydrocinnamic acid; (S)-2-Amino-3-(4-hydroxyphenyl)propionic acid; (S)-2-Amino-3-(p-hydroxyphenyl)propionic acid; (S)-3-(p-Hydroxyphenyl)alanine; (S)-Tyrosine; (S)-alpha-Amino-4-hydroxybenzenepropanoic acid; 2-Amino-3-(p-hydroxyphenyl)propionic acid; 3-(4-Hydroxyphenyl)-L-alanine; 3-(p-Hydroxyphenyl)alanine; 4-Hydroxy-L-phenylalanine; 4ts1

Indication

Disease Entry	ICD 11	Status	REF
Malnutrition	5B50-5B71	Approved	[1]

• Therapeutic Class: Dietary supplement
• Cross-matching ID:
  PubChem CID: 6057
  ChEBI ID: CHEBI:17895
  CAS Number: CAS 60-18-4
  TTD Drug ID: DM9O8DT
  VARIDT Drug ID: DR00020
  INTEDE Drug ID: DR2207

Molecule-Related Drug Atlas

Drug(s) Targeting Tyrosine 3-monooxygenase (TH)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
L-Phenylalanine	DMQXI9F	Malnutrition	5B50-5B71	Approved	[5]
Tetrahydrobiopterin	DMINZ4W	Malnutrition	5B50-5B71	Approved	[6]
Metyrosine	DMBYCU0	Pheochromocytoma	5A75	Approved	[7]
L1-79	DMLHPVW	Autism spectrum disorder	6A02	Phase 2	[8]
ProSavin	DMJ42E6	Parkinson disease	8A00.0	Phase 1/2	[9]
OXB-102	DMXF9DM	Parkinson disease	8A00.0	Phase 1/2	[10]
7,8-dihydrobiopterin	DMQU4XM	Discovery agent	N.A.	Investigative	[11]
alpha-propyldopacetamide	DMQKMX3	Discovery agent	N.A.	Investigative	[12]
Meta-Tyrosine	DM0748C	Discovery agent	N.A.	Investigative	[11]
3-iodotyrosine	DMNZMH6	Discovery agent	N.A.	Investigative	[12]

Drug(s) Transported By L-type amino acid transporter 2 (SLC7A8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
L-Tryptophan	DMIBH7M	Depression	6A70-6A7Z	Approved	[3]
Glycine	DMIOZ29	Allergic rhinitis	CA08.0	Approved	[3]
L-Alanine	DMZDN4W	Dietary shortage	5B5K	Approved	[3]
L-Proline	DMKSTWR	Malnutrition	5B50-5B71	Approved	[3]
L-Phenylalanine	DMQXI9F	Malnutrition	5B50-5B71	Approved	[13]

Drug(s) Metabolized By Tyrosine decarboxylase (tdc)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Levodopa	DMN3E57	Parkinson disease	8A00.0	Approved	[14]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Tyrosine 3-monooxygenase (TH)	TTUHP71	TY3H_HUMAN	Binder	[2]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
L-type amino acid transporter 2 (SLC7A8)	DTJF3DX	LAT2_HUMAN	Substrate	[3]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Tyrosine decarboxylase (tdc) Main DME	DEX2ZLF	TYRDC_LACBR	Substrate	[4]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4791).
• [2] Effect of metals and phenylalanine on the activity of human tryptophan hydroxylase-2: comparison with that on tyrosine hydroxylase activity. Neurosci Lett. 2006 Jul 3;401(3):261-5.
• [3] The Transporter Classification Database (TCDB): recent advances. Nucleic Acids Res. 2016 Jan 4;44(D1):D372-9. (ID: 2.A.3.8.20)
• [4] Tyrosine decarboxylase from Lactobacillus brevis: soluble expression and characterization. Protein Expr Purif. 2014 Feb;94:33-9.
• [5] Selectivity and affinity determinants for ligand binding to the aromatic amino acid hydroxylases. Curr Med Chem. 2007;14(4):455-67.
• [6] Biochemistry of postmortem brains in Parkinson's disease: historical overview and future prospects. J Neural Transm Suppl. 2007;(72):113-20.
• [7] Dopamine beta-hydroxylase deficiency. A genetic disorder of cardiovascular regulation. Hypertension. 1991 Jul;18(1):1-8.
• [8] Effect of L1-79 on Core Symptoms of Autism Spectrum Disorder: A Case Series. Clin Ther. 2019 Oct;41(10):1972-1981.
• [9] Clinical pipeline report, company report or official report of Oxford BioMedica.
• [10] Clinical pipeline report, company report or official report of Oxford BioMedica.
• [11] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [12] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1243).
• [13] Quantifying the relative contributions of different solute carriers to aggregate substrate transport. Sci Rep. 2017 Jan 16;7:40628.
• [14] Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson's disease. Nat Commun. 2019 Jan 18;10(1):310.